iSpecimen Completes Private Placement, Engages IR Consulting Firm

iSpecimen ( (ISPC) ) just unveiled an announcement.

On December 31, 2025, iSpecimen Inc. completed a private placement of its Series C Convertible Non-Voting Preferred Stock and entered into a Consulting Agreement with IR Agency LLC to provide marketing, advertising, and investor communications services for an initial four-month term starting the same day. The consultant, acting as an independent contractor on a non-exclusive basis, received a $2 million cash fee funded from the private placement proceeds, and the agreement—which includes standard contractual protections and can be terminated at any time by either party—signals iSpecimen’s effort to strengthen its market visibility and investor outreach without engaging in securities solicitation activities.

The most recent analyst rating on (ISPC) stock is a Sell with a $0.28 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.

Spark’s Take on ISPC Stock

According to Spark, TipRanks’ AI Analyst, ISPC is a Underperform.

The score is weighed down primarily by deteriorating financial performance (sharp revenue decline, weaker margins, ongoing losses) and persistent cash burn. Technicals also reflect a strong downtrend with bearish momentum. Corporate events add ongoing Nasdaq bid-price delisting risk despite some compliance progress and actions (reverse split approval) to address it.

To see Spark’s full report on ISPC stock, click here.

More about iSpecimen

iSpecimen Inc. (Nasdaq: ISPC) is a Delaware-based company that operates in the life sciences and medical research sector, focusing on connecting researchers with human biospecimens and related data to support scientific and clinical studies.

Average Trading Volume: 1,065,457

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.79M

See more data about ISPC stock on TipRanks’ Stock Analysis page.